Upload
researchonglobalmarketscom
View
216
Download
0
Embed Size (px)
Citation preview
7/29/2019 Healthcare Sector in India Monthly Update November 2012
http://slidepdf.com/reader/full/healthcare-sector-in-india-monthly-update-november-2012 1/12
Healthcare Sector in India
Monthly Update
November 2012
7/29/2019 Healthcare Sector in India Monthly Update November 2012
http://slidepdf.com/reader/full/healthcare-sector-in-india-monthly-update-november-2012 2/12
Top Story
Ireland India tie up for biomaterial research
Ireland‐India relations are being strengthened by The Network of Excellence for FunctionalBiomaterials (NFB) at NUI Galway for the purpose of research in biosciences. The
biomaterials research group of NFB will be tying up with NFB the Materials Research Centre
at the Indian Institute of Science, Bangalore; the Indian Institute of Technology in Kanpur;
the Indian Institute of Technology in New Delhi and the Sree Chitra Tirunal Institute of
edical Science and Technology in Trivandrum for increasing co‐operation andM
communication within the international community of public health research.
NFB focuses on carrying out research on biomaterials to develop technologies with clinical
applications in the fields of orthopedics, soft‐tissue healing and neural and cardiovascular
regeneration. The tie up will facilitate translational activities and commercial exploitation of
developing technologies.
News Update
General
Advanced CT scanner installed in Kolkata diagnostic lab
Kolkata based Pulse Diagnostics Pvt. Ltd. has recently installed a highly advanced Computed
Tomography (CT) scanner that reduces a patient’s exposure to the harmful radiation. The
Wipro GE manufactured device is the 1st of its kind equipment to be installed in easternegion. The equipment is comparatively higher on safety, comfort and accuracy to the regular
T scanners popularly in use.
r
C
Trivitron enters into JV with DiaSorin group
Trivitron Healthcare has collaborated with Italian immunodiagnostic firm DiaSorin S.p.A. The
51:49 joint venture (JV) between DiaSorin and Trivitron respectively has been etched with
the purpose of earning INR 1 bn within 2 years from the Indian market. Trivitron also plans
o manufacture some of Diasorin products from its Chennai located Trivitron’s Medicalt
Technology Park.
Trivitron is planning to strengthen its global reach through partnerships with companiesoperating in imaging and diagnostics space valued above INR 1 bn. The company's recent
arning of INR 4 bn PE fund from Fidelity Growth Partners India is being planned to be
artially used for making acquisitions in the US or Europe.
e
p
Healthcare Sector – Monthly Update
Sanofi to conduct clinical trial of dengue vaccine
Clinical trials of the world’s most effective vaccine candidate against dengue will soon be
conducted in India. The vaccination that has been devised by French pharmaceutical
7/29/2019 Healthcare Sector in India Monthly Update November 2012
http://slidepdf.com/reader/full/healthcare-sector-in-india-monthly-update-november-2012 3/12
company Sanofi Pasteur will be conducting the trials from Thailand to India to judge its
mpact over populations across countries. The drug controller general of India has requestedi
Sanofi to conduct phase II safety trials on adults followed by children.
he clinical trial results that are expected to be published by 2013, will finally aid in the
aunch of the vaccination by 2015.
T
l
L&T to sell off medical equipment business
Engineering company Larsen & Toubro (L&T) will be selling off its independent Mysore‐
ased medical equipment business to Mysore based Skanray Healthcare Pvt. Ltd. for anb
undisclosed amount.
The medical equipment business unit initiated in 1987 operated under L&T’s electrical and
automation (EA) unit and was into manufacturing of hospital medical equipments such as
patient monitors, ECG machines, syringe pumps, anesthesia delivery systems, ventilators,defibrillators, cardiac resuscitation systems, ultrasound and colour Doppler imaging, X‐ray
nd C‐Arm image intensifiers, hospital turnkey projects, telemedicine solutions and specialty
mbulances.
a
a
GSK to invest in its Indian consumer healthcare subsidiary
British drug maker GlaxoSmithKline (GSK) will be investing INR 52.15 bn to increase its
stake in Indian consumer healthcare subsidiary, GlaxoSmithKline Consumer Healthcare
(GSKCH). The investment will be made through a voluntary open offer. GSK that was initially
holding 43.2% stake in GSKCH, by purchasing 31.8% of the total outstanding shares at a
rice of INR 3,900 per share will as a result make GSK 75% stake owner of the public listedp
Indian company GSKCH.
The high investment buyback is an indication of the parent company’s confidence in
merging markets like India. The transaction will see GSKCH become a subsidiary of GSK
rom its initial position of being an associate company.
e
f
News Update
Regulatory CSIR soon to conduct clinical trial for tuberculosis
The Council for Scientific and Industrial Research (CSIR) will soon be conducting 1st phase of
clinical trial for tuberculosis in the next few months. The clinical trial will take place through
the Open Source Drug Discovery model which is a consortium led by CSIR in collaboration
with global drug companies aimed at solving complex problems associated with discovering
novel therapies for diseases. CSIR was allocated INR 0.5 bn during the 11th Five Year Plan
Healthcare Sector – Monthly Update
7/29/2019 Healthcare Sector in India Monthly Update November 2012
http://slidepdf.com/reader/full/healthcare-sector-in-india-monthly-update-november-2012 4/12
and it has further laid down a proposal of INR 6 bn for carrying out clinical trial in the 12 th
Five Year Plan.
In spite of the potential Indian tuberculosis market projects, there are currently no MNC drugmakers involved in drug discovery and its research. CSIR’s initiative in tuberculosis drug
discovery will bring relief to a large population that die in India every year.
News Update
Expansion Plans Intas enters agreement with Mayne Pharma
Ahmadabad based Intas Pharmaceuticals has recently etched a licensing deal with Australian
pharma company Mayne Pharma Corporation. Intas has agreed to supply 11 injectable
products for the Australian market. The products will be marketed in Australia under
ayne’s brand name and the company plans to file the products with the Therapeutic GoodsM
Administration (TGA) during 2013 calendar year.
Intas has been relying on companies with global reach to market its products internationally.
Prior to this deal, Intas has also signed agreements with Australia based Phosphagenics Ltd.
and UK based AstraZeneca for marketing of its products.
Miral introduces pharma products in Sierra Leone
Gurgaon based Miral Health Care Ltd. has made a move to distribute more than 30 medicinesand hospital consumables in Sierra Leone. The initiative has been undertaken solely for
improving the availability of pharma products in hospitals, clinics and pharmacies that faces
a severe dearth across the country. The products being distributed and marketed are World
ealth Organization (WHO) certified as well as registered with the Pharmacy Board of SierraH
Leone.
Miral has been focusing at distribution of drugs for the most common diseases like anemia of
ll cases, typhoid, fever, headache and general body pain along with treatment of feverish
ondition, cold symptoms, toothache, headaches and general body pain.
a
c
Spherix
and
Fullife
partners
to
popularize
D-
tagatose
Bethesda (in USA) located Spherix Incorporated and Mumbai based Fullife Healthcare Pvt.
Ltd. has entered into a partnership that seals a supply and license agreement for the use of D‐
tagatose in India. Fullife has been granted the exclusive right for use of nutraceutical
product’s clinical data and proprietary know‐how to support marketing and dosing of D‐
agatose in India by Spherix. By the agreement, Fullife will pay a fixed royalty on gross sales
o Spherix for D‐tagatose that will be used as supplement in food or cosmetic products.
t
t
Healthcare Sector – Monthly Update
7/29/2019 Healthcare Sector in India Monthly Update November 2012
http://slidepdf.com/reader/full/healthcare-sector-in-india-monthly-update-november-2012 5/12
T
d
he product being an adaptable compound can be formulated in several ways to help
iabetic and patients with metabolic syndrome cope with their disorders.
Cipla plans
majority
stake
holding
in
Cipla
Medpro
Mumbai based Cipla Ltd. is in plans to acquire a majority 51% stake in Cipla Medpro South
frica Ltd., Cipla’s distribution partner of South Africa along with a few other neighboringA
markets. Cipla will be investing close to INR 12.10 bn for the transaction.
Medpro operates in 2 divisions – Cape Town based Medpro that distributes a range of
chronic ailments and OTC medications. The other being, Durban based Cipla Medpro
Manufacturing which is the 1st international PIC/S‐compliant pharmaceutical manufacturing
acilities of South Africa. The manufacturing division is into production of selective products
nd also offers contract manufacturing solutions to local and multinational companies.
f
a
Industry Expert Speak
Trivitron enters into JV with Diasorin group - G S K Velu, Managing Director of Trivitron Group “Diasorin has been doing INR 2 bn business in India and the association with Trivitron will
help it scale its distribution network and garner INR 1 bn in 2 years. Immunoassaying, which
accounts for 40% of the total INR 25 bn diagnostic market in the country, is dominated by
ulti‐national companies like Abbots, Siemens and Rosch. The market for immunoassaying
as been growing faster at 25% than the entire diagnostics market.”
m
h
GSK to invest in its Indian consumer healthcare - David Redfern, Chief Strategy Officer, GSK "GSK Consumer Healthcare is a well established business in India and its leading product,
Horlicks, is an iconic household brand. This transaction represents a further step in GSK's
trategy to invest in the world's fastest growing markets and, we believe, offers a liquidity
pportunity at an attractive premium for existing shareholders,"
s
o
CSIR soon to conduct clinical trial for tuberculosis - Samir K Brahmachari, Director General, CSIR “With a vision to reduce the number substantially and eradicate TB completely by 2022, we
re taking various such initiatives on similar models like how the country achieved success in
radicating polio.”
a
e
Healthcare Sector – Monthly Update
7/29/2019 Healthcare Sector in India Monthly Update November 2012
http://slidepdf.com/reader/full/healthcare-sector-in-india-monthly-update-november-2012 6/12
Transaction Detail (Sep – Nov 2012)
Date Buyer Target Deal Size
(INR mn) % stake Deal Status
Type of
Transaction
26 vth No2012
Trivitron
Healthcare Pvt.Ltd.
Ani LabsystemsLtd.
1221.12 N.A. Completed Acquisition
22 vnd No2012
IncuCapital
Navigene
Genetic SciencePvt. Ltd.
N.A. N.A. Completed Private Equity
21st Nov2012
Cipla Ltd.Cipla Medpro
South Africa Ltd.12101.2 51% Completed Acquisition
8th Nov2012
Sun PharmaIndustries Ltd.
DUSA
Pharmaceuticals,Inc.
12.65 N.A. Planned Acquisition
3 t 1st Oc2012
GE EquityInternational
Mauritius
Syngene
(Biocon Ltd.
subsidiary)
International1250 7.69 Completed Private Equity
2 t 5th Oc
2012
Fidelity India
Capital
Trivitron
Healthcare4000 35‐40 Planned Private Equity
2 t 2nd Oc2012
Dr. Reddy'sLaboratories
OctoPlus N.V. 1930 100 Planned Acquisition
1 t 7th Oc
2012
Mylan
Laboratories
SMS
Pharmaceuticals’Vishakhapatnam
locatedmanufacturing
1730 N.A. Completed Acquisition
27th Sep2012
Norwest VenturePartners
ThyrocareTechnologies
1200 10 Completed Private Equity
Healthcare Sector – Monthly Update
7/29/2019 Healthcare Sector in India Monthly Update November 2012
http://slidepdf.com/reader/full/healthcare-sector-in-india-monthly-update-november-2012 7/12
12th Sep2012
Avigo CapitalPartners
Super ReligareLaboratories
2,916.79 N.A. Planned Private Equity
12th Sep2012
IndoUS
VenturePartners
Vyome
Biosciences Pvt Ltd.
185 N.A. Planned Private Equity
11th Sep2012
Norwest VenturePartners
ThyrocareTechnologies
Ltd1166.71 10 Planned Private Equity
5th Sep
2012
Norwest
Venture
Partners
NationWide
Primary
HealthcareServices Pvt. Ltd.
250 N.A. Completed Private Equity
Annual Financial Results – Revenue (INR mn) – Major Healthcare
Companies Companies FY ’09 FY ’10 FY ’11 FY’ 12
Biocon Ltd. 16,492.50 23,932.70 27,947.70 21,483.0
Blue Star Ltd. 25,026.2 25,249.7 29,536.8 27,888.5
Cadila Healthcare Ltd. 29,066.00 35,780.00 44,671.00 50,899.7
Cipla Ltd. 52,876.20 56,704.00 63,850.70 68,477.0
Dabur India Ltd. 28,122.40 33,958.00 40,817.40 52,832.0
Dr. Reddy’s Laboratories
(DRL)69,441.00 70,277.00 74,693.00 96,737.4
GlaxosmithKline
Consumer HealthcareLtd.
19,757.6 23,693.3 27,688.6 28,857.3
Glenmark
Pharmaceuticals Ltd.21,241.20 25,291.30 29,490.70 40,206.4
Jubilant life Sciences Ltd. 35,491.00 38,047.80 34,484.40 42,539.5
Lupin Ltd. 38,508.30 48,318.10 57,851.90 70,829.1
Healthcare Sector – Monthly Update
7/29/2019 Healthcare Sector in India Monthly Update November 2012
http://slidepdf.com/reader/full/healthcare-sector-in-india-monthly-update-november-2012 8/12
Nestle India Ltd. 51,395.5 62,609.4 74,994.6 77,409.0
Opto Circuits (India) Ltd. 8,185.197 10,775.826 15,855.631 23,568.543
Piramal Healthcare Ltd. 32,478.20 36,276.30 25,157.70 20,838.3
Ranbaxy Laboratories
Ltd.75,970.40 89,607.70 101,614.1 117,153.2
Siemens India Ltd. 93,070.2 96,272.4 119,718.1 124,657.9
Strides Arcolab Ltd. 13,101.6 16,958.4 25,245.2 25,645.1
Sun Pharmaceuticals
Industries Ltd.42,723.00 38,086.30 57,214.30 80,056.6
Torrent Pharmaceuticals
Ltd.
16,306.60 19,160.40 22,264.80 26,959.2
Wockhardt Ltd. 3,6294.4* 36,477.60 37,633.50 46,138.0
Annual Financial Results – Income (INR mn) - Major Healthcare
Companies
Companies F Y ’09 FY ’10 FY ’11 FY’ 12
Biocon Ltd. 931.2 2,932.40 3,675.20 3,384.0
Blue Star Ltd. 1,802.9 2,114.9 1,609.6 ‐1,051.0
Cadila Healthcare Ltd. 3,031.00 5,051.00 7,110.00 6,525.9
Cipla Ltd. 7,710.20 10,825.90 9,895.70 11,442.4
Dabur India Ltd. 3,905.00 5,010.80 5,685.70 6,449.0
Dr. Reddy’s Laboratories
(DRL) ‐5,168.00 1,068.00 11,040.00 14,262.1
GlaxoSmithKline Consumer
Healthcare Ltd.2,327.8 2,998.5 3,552.1 3,765.6
Glenmark Pharmaceuticals
Ltd.1,916.60 3,244.70 4,532.10 4,603.5
Healthcare Sector – Monthly Update
7/29/2019 Healthcare Sector in India Monthly Update November 2012
http://slidepdf.com/reader/full/healthcare-sector-in-india-monthly-update-november-2012 9/12
Jubilant life Sciences Ltd. 2,831.80 4,214.60 2,297.20 145.6
Lupin Ltd. 5,015.40 6,816.30 8,625.50 8,676.5
Nestle India Ltd. 6,550.0 8,186.6 9,615.5 9,815.7
Opto Circuits (India) Ltd. 2,087.3 2,603.0 3,672.5 5,718.8
Piramal Healthcare Ltd. 3,162.50 4,819.00 128,833.60 1,115.0
Ranbaxy Laboratories Ltd. 2,964.90 14,967.50 ‐28,997.3 ‐19,573.5
Siemens India Ltd. 7,046.0 7,577.7 8,677.5 7,300.6
Strides Arcolab Ltd. 1,096.80 1,224.50 2,244.8 8,258.4
Sun Pharmaceuticals
Industries Ltd.18,177.30 13,510.80 18,160.60 25,872.5
Torrent Pharmaceuticals Ltd. 1,843.70 2,312.00 2,701.70 2,840.4
Wockhardt Ltd. ‐4,355.4* ‐9,804.20 905.2 3,427.1
Quarterly Financial Results – Revenue (INR mn) – Major Healthcare
Companies Companies
Oct -Dec
2011
Jan-Mar
2012
Apr-Jun
2012
Jul-Sep
2012
Biocon Ltd. 5,171.90 5,892.2 5,770.0 5,924.0
Blue Star Ltd. 5,896.9 N.A. N.A. N.A.
Cadila Healthcare Ltd. 13,524.60 14 .9,633 15 .0,161 15 .0,125
Cipla Ltd. 17,580.00 N.A N.A. N.A.
Healthcare Sector – Monthly Update
7/29/2019 Healthcare Sector in India Monthly Update November 2012
http://slidepdf.com/reader/full/healthcare-sector-in-india-monthly-update-november-2012 10/12
Dabur India Ltd. 14,526.80 13,858.3 14,620.0 15,226.0
Dr. Reddy’s Laboratories
(DRL)27,692.00 26,584.0 25,406.0 28,808.5
GlaxoSmithKline ConsumerHealthcare Ltd.
6,854.0 8,608.7 7,869.6 8,275.4
Glenmark Pharmaceuticals
Ltd.10,310.90 10,751.2 10,404.1 12,551.9
Jubilant life Sciences Ltd. 10,871.70 12,235.9 12,358.9 12,197.3
Lupin Ltd. 17,917.0 20,063.7 22,191.5 22,392.6
Nestle India Ltd. 19,633.2 20,558.7 19,865.8 21,155.9
Opto Circuits (India) Ltd. 6,112.9 6,627.0 7,150.6 6,070.1
Piramal Enterprises Ltd. 5,518.30 8,858.0 7,102.9 8,285.8
Ranbaxy Laboratories Ltd. 37,923.1 36,954.0 31,740.6 26,513.9
Siemens India Ltd. 30,458.2 37 2601.43 33,082.4 32,693.6
Strides Arcolab Ltd. 6,864.7 5,274.7 5,082.9 5,773.4
Sun Pharmaceuticals
Industries Ltd.21,451.30 23,299.3 26,581.4 26,572.4
Torrent Pharmaceuticals Ltd. 6,965.9 6,686.8 7,356.0 7,471.7
Wockhardt Ltd. 12,086.70 12,413.90 14,258.2 13,474.4
Companies Oct
-Dec
2011
Jan-Mar
2012
Apr-Jun
2012
Jul-Sep
2012
Biocon Ltd. 848.50 978.0 790.0 896.5
Blue Star Ltd. (327.6) N.A. N.A. N.A.
Cadila Healthcare Ltd. 1,492.10 1,708.8 1,947.9 951.4
Quarterly Financial Results – Income (INR mn) - Major Healthcare
Com anies
Healthcare Sector – Monthly Update
7/29/2019 Healthcare Sector in India Monthly Update November 2012
http://slidepdf.com/reader/full/healthcare-sector-in-india-monthly-update-november-2012 11/12
Cipla Ltd. 2,699.10 N.A. N.A. N.A.
Dabur India Ltd. 1,728.20 1,705.1 1,494.0 2,023.7
Dr. Reddy’s Laboratories(DRL)
5,130.0 3,427.0 3,360.0 4,074.4
GlaxoSmithKline Consumer
Healthcare Ltd.591.0 1,319.7 1,066.0 1,285.5
Glenmark PharmaceuticalsLtd.
461.20 1,482.7 782.8 1,567.5
Jubilant life Sciences Ltd. ‐783.90 ‐635.3 50.1 1,520.0
Lupin Ltd. 2,350.60 1,556.4 2,803.9 2,904.6
Nestle India 2,308.30 2,757.3 2,459.7 2,673.1
Opto Circuits (India) Ltd. 1,250.8 2,093.5 1,380.2 1,162.4
Piramal Enterprises Ltd. 85.2 ‐386.8 40.8 (920.2)
Ranbaxy Laboratories Ltd. ‐29,827.7 12,467.6 ‐5,857.3 7,541.7
Siemens India Ltd. 1,873.6 3,040.0 (157.8) (557.7)
Strides Arcolab Ltd 684.1 6,420.7 904.8 524.9
Sun Pharmaceuticals
Industries Ltd. 6,683.0 8202.1 7,955.5 3,196.4
Torrent Pharmaceuticals Ltd 831.8 ‐16.5 1,018.5 1,072.5
Wockhardt Ltd. 2,128.10 ‐1,916.4 3,779.7 4,535.5
* denotes a change in financial year
Healthcare Sector – Monthly Update
7/29/2019 Healthcare Sector in India Monthly Update November 2012
http://slidepdf.com/reader/full/healthcare-sector-in-india-monthly-update-november-2012 12/12
Events Calendar
1st International Fellowship on Health
Techn loo gy Assessment
ate: 9
D th –16th Dec, 2012Venue: Am
A
rita Institute of Medical Sciences at
iencesmriteshwari Hall
dical ScOrganizer: Amrita Institute Of MeWebsite: http://www.aimshospital.org/ Contact Person: Dr. Sanjeev SinghContact No.: +91‐484‐6681234
Biofest -2012 International Bio Conference and
Event
Date: 12th‐13th Dec, 2012Venue: Leonia International Centre for
Exhibitions & Conventions, HyderabadOrganize ferences &r: Bright International Con
Event Website:
s Organizationhttp://www.brightice.org
Contact Person: Hari KrishnaContact No.: +91‐40‐64540825
Research on India (ROI) is a leading source for market research on various sectors in India
hat offers premium research content from worldwide publishers of market researcht
reports.
Contact us:
mW: https://www.researchonindia.co
; International: +91 (33) 4027 6214/5T
E
: India (Toll Free): 1800 102 1133
Connect with Us
Disclaimer: This monthly update is published for general information only based on press articles and company releases. Research on India has not independently verified any of information and is not responsible for any loss or damage arising from use of this document.
Healthcare Sector – Monthly Update